548 related articles for article (PubMed ID: 28805815)
1. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Chow RD; Guzman CD; Wang G; Schmidt F; Youngblood MW; Ye L; Errami Y; Dong MB; Martinez MA; Zhang S; Renauer P; Bilguvar K; Gunel M; Sharp PA; Zhang F; Platt RJ; Chen S
Nat Neurosci; 2017 Oct; 20(10):1329-1341. PubMed ID: 28805815
[TBL] [Abstract][Full Text] [Related]
2. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
3. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Eisemann T; Costa B; Harter PN; Wick W; Mittelbronn M; Angel P; Peterziel H
Neuro Oncol; 2019 Feb; 21(3):326-336. PubMed ID: 30418623
[TBL] [Abstract][Full Text] [Related]
5. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
7. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Yip S; Miao J; Cahill DP; Iafrate AJ; Aldape K; Nutt CL; Louis DN
Clin Cancer Res; 2009 Jul; 15(14):4622-9. PubMed ID: 19584161
[TBL] [Abstract][Full Text] [Related]
8. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
[No Abstract] [Full Text] [Related]
9. Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Zhang F; Liu R; Zhang H; Liu C; Liu C; Lu Y
BMC Cancer; 2020 Jul; 20(1):673. PubMed ID: 32682409
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
11. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Schaich M; Kestel L; Pfirrmann M; Robel K; Illmer T; Kramer M; Dill C; Ehninger G; Schackert G; Krex D
Ann Oncol; 2009 Jan; 20(1):175-81. PubMed ID: 18687982
[TBL] [Abstract][Full Text] [Related]
12. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Maciaczyk D; Picard D; Zhao L; Koch K; Herrera-Rios D; Li G; Marquardt V; Pauck D; Hoerbelt T; Zhang W; Ouwens DM; Remke M; Jiang T; Steiger HJ; Maciaczyk J; Kahlert UD
Br J Cancer; 2017 Jun; 117(1):102-112. PubMed ID: 28571041
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
MacLeod G; Bozek DA; Rajakulendran N; Monteiro V; Ahmadi M; Steinhart Z; Kushida MM; Yu H; Coutinho FJ; Cavalli FMG; Restall I; Hao X; Hart T; Luchman HA; Weiss S; Dirks PB; Angers S
Cell Rep; 2019 Apr; 27(3):971-986.e9. PubMed ID: 30995489
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
15. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening.
Wang G; Chow RD; Ye L; Guzman CD; Dai X; Dong MB; Zhang F; Sharp PA; Platt RJ; Chen S
Sci Adv; 2018 Feb; 4(2):eaao5508. PubMed ID: 29503867
[TBL] [Abstract][Full Text] [Related]
16. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
18. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi ME; Stupp R
Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
[No Abstract] [Full Text] [Related]
19. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling.
Zuckermann M; Hovestadt V; Knobbe-Thomsen CB; Zapatka M; Northcott PA; Schramm K; Belic J; Jones DT; Tschida B; Moriarity B; Largaespada D; Roussel MF; Korshunov A; Reifenberger G; Pfister SM; Lichter P; Kawauchi D; Gronych J
Nat Commun; 2015 Jun; 6():7391. PubMed ID: 26067104
[TBL] [Abstract][Full Text] [Related]
20. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
